Evidence map›Paper›PMID 36289664›Full record

ArticleBiomedicines2022

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers.

Alessio Danilo Inchingolo, Giuseppina Malcangi, Sabino Ceci, Assunta Patano, Alberto Corriero, Daniela Azzollini, Grazia Marinelli, Giovanni Coloccia, Fabio Piras, Giuseppe Barile and 19 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 5 institutions in 2 countries.

Alessio Danilo InchingoloDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-6366-1039
Giuseppina MalcangiDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0001-9745-7506
Sabino CeciDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-7839-4623
Assunta PatanoDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0001-7395-3126
Alberto CorrieroDepartment of Interdisciplinary Medicine, Intensive Care Unit Section, Aldo Moro University, 70121 Bari, Italy.ORCID 0000-0002-9760-9394
Daniela AzzolliniDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-1307-8582
Grazia MarinelliDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0001-9163-2350
Giovanni ColocciaDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-1327-5762
Fabio PirasDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-0765-7710
Giuseppe BarileDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-4027-4105
Vito SettanniDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-4145-3455
Antonio ManciniDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-7103-4086
Nicole De LeonardisDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-1974-3475
Grazia GarofoliDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Giulia PalmieriDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-0292-1965
Ciro Gargiulo IsaccoDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Biagio RaponeDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-0062-6594
Megan JonesDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
Ioana Roxana BordeaDepartment of Oral Rehabilitation, Faculty of Dentistry, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-7166-9949
Gianluca Martino TartagliaUOC Maxillo-Facial Surgery and Dentistry, Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, University of Milan, 20100 Milan, Italy.
Antonio ScaranoDepartment of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.
Felice LorussoDepartment of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.ORCID 0000-0002-2660-9231
Luigi MacchiaDepartment of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", 70124 Bari, Italy.
Angela Maria Vittoria LaroccaHygiene Complex Operating Unit, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Place Giulio Cesare, 11, 70124 Bari, Italy.
Silvio TafuriDepartment of Biomedical Science and Human Oncology, University of Bari, 70121 Bari, Italy.ORCID 0000-0003-4194-0210
Giovanni MiglioreUniversity Hospital of Bari, 70120 Bari, Italy.
Nicola BrienzaDepartment of Interdisciplinary Medicine, Intensive Care Unit Section, Aldo Moro University, 70121 Bari, Italy.
Gianna DipalmaDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0002-5947-8987
Francesco InchingoloDepartment of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.ORCID 0000-0003-3797-5883
University of Bari Aldo Moro · ITUniversity of Chieti-Pescara · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITIuliu Hațieganu University of Medicine and Pharmacy · ROUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients' activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari "Aldo Moro" led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.

Indexed as

antibodiesantispikeboosterCOVID-19dentistryMERSPfizerSARS-CoV-1SARS-CoV-2vaccines

Identifiers

PMID36289664
PMCPMC9598246
OpenAlexW4297347913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.